Cargando…
Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061553/ https://www.ncbi.nlm.nih.gov/pubmed/33986566 http://dx.doi.org/10.2337/cd20-0121 |
| _version_ | 1783681588964360192 |
|---|---|
| author | Fonseca, Vivian A. Sood, Minisha Galindo, Rodolfo J. |
| author_facet | Fonseca, Vivian A. Sood, Minisha Galindo, Rodolfo J. |
| author_sort | Fonseca, Vivian A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8061553 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80615532022-04-01 Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary Fonseca, Vivian A. Sood, Minisha Galindo, Rodolfo J. Clin Diabetes Clinical Diabetes Digital Publication American Diabetes Association 2021-04 /pmc/articles/PMC8061553/ /pubmed/33986566 http://dx.doi.org/10.2337/cd20-0121 Text en © 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. |
| spellingShingle | Clinical Diabetes Digital Publication Fonseca, Vivian A. Sood, Minisha Galindo, Rodolfo J. Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary |
| title | Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary |
| title_full | Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary |
| title_fullStr | Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary |
| title_full_unstemmed | Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary |
| title_short | Rationale for the Use of Combination Injectable Therapy in Patients With Type 2 Diabetes Who Have High A1C (≥9%) and/or Long Duration (>8 Years): Executive Summary |
| title_sort | rationale for the use of combination injectable therapy in patients with type 2 diabetes who have high a1c (≥9%) and/or long duration (>8 years): executive summary |
| topic | Clinical Diabetes Digital Publication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061553/ https://www.ncbi.nlm.nih.gov/pubmed/33986566 http://dx.doi.org/10.2337/cd20-0121 |
| work_keys_str_mv | AT fonsecaviviana rationalefortheuseofcombinationinjectabletherapyinpatientswithtype2diabeteswhohavehigha1c9andorlongduration8yearsexecutivesummary AT soodminisha rationalefortheuseofcombinationinjectabletherapyinpatientswithtype2diabeteswhohavehigha1c9andorlongduration8yearsexecutivesummary AT galindorodolfoj rationalefortheuseofcombinationinjectabletherapyinpatientswithtype2diabeteswhohavehigha1c9andorlongduration8yearsexecutivesummary |